Sanofi SNY announced preliminary data from the phase II TIDE-Asthma study, which evaluated its anti-OX40L mAb, amlitelimab, ...

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients with heterogeneous inflammatory asthma. This would “potentially represent ...

Sanofi (NASDAQ:SNY) announced Tuesday that its TIDE-Asthma Phase 2 study for its T-cell-depleting monoclonal antibody ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...

Here is the complete list of companies whose shares will trade ex-date on April 17, 2025, along with their key corporate ...

BNP Paribas Exane initiated coverage of Sanofi (SNY) with an Outperform rating and $65 price target Stay Ahead of the Market: Discover ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

Sanofi has said “deal” to Chrissy Teigen. The model, cookbook author and “Deal or No Deal” banker has signed on as a celebrity spokesperson for Sanofi’s push to encourage people to screen early for ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has ...

The French pharmaceutical major has reportedly slashed the asking price for Lantus from an initial Rs 3,000 crore to Rs 2,000 crore, in a bid to draw more interest.